Clinical effectiveness of droplet digital polymerase chain reaction technology for human epidermal growth factor receptor 2/neu gene testing in breast cancer compared to conventional methods
International Journal of Health Sciences · 2026
DOI: 10.25259/ijhs_50_2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Health Sciences, 2026. Verfasst von Maryam Hassan Al-Zahrani und 3 weiteren Autor:innen. Die Arbeit nennt 78 Literaturangaben.
Abstract (Originalsprache)
Objectives
Breast cancer (BC) is the most common cancer in women worldwide and has poor survival outcomes. The human epidermal growth factor receptor 2 (HER2), a key promoter of tumor progression and metastasis, is overexpressed or amplified in 15–20% of BC cases, leading to worse prognosis. The introduction of anti-HER2 monoclonal antibodies has significantly improved survival in advanced HER2-positive BC. Current HER2 testing in routine diagnostic practice relies on immunohistochemistry (IHC) and in situ hybridizations (ISH) techniques as US Food and Drug Administration-approved methods. However, these standard methods still have some limitations related to subjectivity, reproducibility, accuracy, and cost. To overcome these challenges, this study investigated droplet-based digital polymerase chain reaction (ddPCR) as a breakthrough technology for absolute DNA quantification.
Methods
The ddPCR is a reliable third-generation PCR-based technology that has higher sensitivity, accuracy, and reproducibility. The HER2 gene status testing was assessed using ddPCR in a retrospective cohort of 36 formalin-fixed and paraffin-embedded tissues from BC patients with invasive ductal carcinoma.
Results
Our results showed that ddPCR has very high concordance rates of 81% and 83% with IHC and brightfield double ISH (BDISH), respectively.
Conclusion
These findings highlight the high accuracy and concordance of ddPCR with both BDISH and IHC, emphasizing its potential usefulness for HER2 testing in BC. After further optimization and standardization in larger cohorts, ddPCR hold the promise to become a rapid, reliable, and cost-effective alternative method suitable for the accurate assessment of HER2 gene status and other amplification-based genes for oncotherapies.
Zitieren
APA
Al-Zahrani, M. H., Jafri, M. A., Buhmeida, A., & Assidi, M. (2026). Clinical effectiveness of droplet digital polymerase chain reaction technology for human epidermal growth factor receptor 2/neu gene testing in breast cancer compared to conventional methods. International Journal of Health Sciences. https://doi.org/10.25259/ijhs_50_2025
Vancouver
Al-Zahrani MH, Jafri MA, Buhmeida A, Assidi M. Clinical effectiveness of droplet digital polymerase chain reaction technology for human epidermal growth factor receptor 2/neu gene testing in breast cancer compared to conventional methods. International Journal of Health Sciences. 2026. doi:10.25259/ijhs_50_2025
BibTeX
@article{AlZahrani2026,
author = {Al-Zahrani, Maryam Hassan and Jafri, Mohammad Alam and Buhmeida, Abdelbaset and Assidi, Mourad},
title = {Clinical effectiveness of droplet digital polymerase chain reaction technology for human epidermal growth factor receptor 2/neu gene testing in breast cancer compared to conventional methods},
journal = {International Journal of Health Sciences},
year = {2026},
doi = {10.25259/ijhs_50_2025}
}
EUVIMED